Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643377
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment MK-0616-032
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-Label Multiple-Dose Clinical Study to Evaluate the Pharmacokinetics of Enlicitide in Participants With Severe Renal Impairment
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol LDL-C in a persons blood Enlicitide decanoate will be called enlicitide from this point forward The purpose of this study is to learn what happens to enlicitide in a persons body over time a pharmacokinetic PK study Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment meaning the kidneys do not work properly and to people who are in good health The researchers believe that the total amount of enlicitide in a persons body measured during the 24 hours after a dose will be similar in people with severe renal impairment and in healthy people
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None